Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-24-003558
Filing Date
2024-11-08
Accepted
2024-11-08 16:08:03
Documents
42
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2432201.htm   iXBRL 10-Q 878535
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 12661
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 12517
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 5020
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 4740
  Complete submission text file 0001178913-24-003558.txt   3897203

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE entx-20240930.xsd EX-101.SCH 55350
7 XBRL CALCULATION FILE entx-20240930_cal.xml EX-101.CAL 28598
8 XBRL DEFINITION FILE entx-20240930_def.xml EX-101.DEF 65270
9 XBRL LABEL FILE entx-20240930_lab.xml EX-101.LAB 796953
10 XBRL PRESENTATION FILE entx-20240930_pre.xml EX-101.PRE 162130
44 EXTRACTED XBRL INSTANCE DOCUMENT zk2432201_htm.xml XML 316349
Mailing Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002
Business Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002 972-2-532-7151
Entera Bio Ltd. (Filer) CIK: 0001638097 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38556 | Film No.: 241440578
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)